• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在神经胶质瘤中 FUBP1 表达缺失预示着 FUBP1 突变,并且与少突胶质细胞分化、IDH1 突变和 1p/19q 杂合性缺失相关。

Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.

机构信息

Institute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany.

出版信息

Neuropathol Appl Neurobiol. 2014 Feb;40(2):205-16. doi: 10.1111/nan.12088.

DOI:10.1111/nan.12088
PMID:24117486
Abstract

AIMS

The Far Upstream Element [FUSE] Binding Protein 1 (FUBP1) regulates target genes, such as the cell cycle regulators MYC and p21. FUBP1 is up-regulated in many tumours and acts as an oncoprotein by stimulating proliferation and inhibiting apoptosis. Recently, FUBP1 mutations were identified in approximately 15% of oligodendrogliomas. To date, all reported FUBP1 mutations have been predicted to inactivate FUBP1, which suggests that in contrast to most other tumours FUBP1 may act as a tumour suppressor in oligodendrogliomas.

METHODS

As no data are currently available concerning FUBP1 protein levels in gliomas, we examined the FUBP1 expression profiles of human glial tumours by immunohistochemistry and immunofluorescence. We analysed FUBP1 expression related to morphological differentiation, IDH1 and FUBP1 mutation status, 1p/19q loss of heterozygosity (LOH) as well as proliferation rate.

RESULTS

Our findings demonstrate that FUBP1 expression levels are increased in all glioma subtypes as compared with normal central nervous system (CNS) control tissue and are associated with increased proliferation. In contrast, FUBP1 immunonegativity predicted FUBP1 mutation with a sensitivity of 100% and a specificity of 90% in our cohort and was associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity (LOH). Using this approach, we detected a to-date undescribed FUBP1 mutation in an oligodendroglioma.

CONCLUSION

In summary, our data indicate an association between of FUBP1 expression and proliferation in gliomas. Furthermore, our findings present FUBP1 immunohistochemical analysis as a helpful additional tool for neuropathological glioma diagnostics predicting FUBP1 mutation.

摘要

目的

远上游元件(FUSE)结合蛋白 1(FUBP1)调节靶基因,如细胞周期调节剂 MYC 和 p21。FUBP1 在许多肿瘤中上调,并通过刺激增殖和抑制凋亡发挥癌蛋白作用。最近,在大约 15%的少突胶质细胞瘤中鉴定出 FUBP1 突变。迄今为止,所有报道的 FUBP1 突变都被预测会使 FUBP1 失活,这表明与大多数其他肿瘤相反,FUBP1 可能在少突胶质细胞瘤中作为肿瘤抑制因子发挥作用。

方法

由于目前尚无关于神经胶质瘤中 FUBP1 蛋白水平的数据,我们通过免疫组织化学和免疫荧光法检查了人类神经胶质瘤的 FUBP1 表达谱。我们分析了 FUBP1 表达与形态分化、IDH1 和 FUBP1 突变状态、1p/19q 杂合性丢失(LOH)以及增殖率的关系。

结果

我们的研究结果表明,与正常中枢神经系统(CNS)对照组织相比,所有神经胶质瘤亚型的 FUBP1 表达水平均升高,并与增殖增加相关。相反,FUBP1 免疫阴性预测 FUBP1 突变在我们的队列中具有 100%的敏感性和 90%的特异性,并且与少突胶质细胞分化、IDH1 突变和 1p/19q 杂合性丢失(LOH)相关。使用这种方法,我们在一个少突胶质细胞瘤中检测到了一个迄今为止尚未描述的 FUBP1 突变。

结论

总之,我们的数据表明 FUBP1 表达与神经胶质瘤的增殖之间存在关联。此外,我们的研究结果表明,FUBP1 免疫组织化学分析可作为神经病理胶质瘤诊断的有用辅助工具,预测 FUBP1 突变。

相似文献

1
Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.在神经胶质瘤中 FUBP1 表达缺失预示着 FUBP1 突变,并且与少突胶质细胞分化、IDH1 突变和 1p/19q 杂合性缺失相关。
Neuropathol Appl Neurobiol. 2014 Feb;40(2):205-16. doi: 10.1111/nan.12088.
2
Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.胶质瘤中1p36和19q13的等位基因缺失:与组织学分类的相关性、1p36上150kb最小缺失区域的定义以及CAMTA1作为候选肿瘤抑制基因的评估
Clin Cancer Res. 2005 Feb 1;11(3):1119-28.
3
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.少突胶质细胞瘤、少突星形细胞瘤和星形细胞瘤中的 CIC 和 FUBP1 突变。
Acta Neuropathol. 2012 Jun;123(6):853-60. doi: 10.1007/s00401-012-0993-5. Epub 2012 May 17.
4
[Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].[1号和19号染色体杂合性缺失与胶质瘤中MGMT、p53和Ki-67蛋白表达的相关性]
Zhonghua Zhong Liu Za Zhi. 2011 Oct;33(10):752-8.
5
Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.少突胶质细胞瘤的分子背景:1p/19q、异柠檬酸脱氢酶(IDH)、端粒酶逆转录酶(TERT)、CIC和FUBP1
CNS Oncol. 2015;4(5):287-94. doi: 10.2217/cns.15.32. Epub 2015 Nov 6.
6
Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors.CIC 和 FUBP1 表达缺失是少突胶质细胞瘤复发时间更短的潜在标志物。
Mod Pathol. 2014 Mar;27(3):332-42. doi: 10.1038/modpathol.2013.165. Epub 2013 Sep 13.
7
Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.IDH1-R132H 突变型而非非典型 IDH1/2 突变和 1p/19q 联合缺失型少突胶质细胞瘤中频繁出现 H3K27 三甲基化丢失:一项日本队列研究。
Acta Neuropathol Commun. 2021 May 21;9(1):95. doi: 10.1186/s40478-021-01194-7.
8
ETV/Pea3 family transcription factor-encoding genes are overexpressed in CIC-mutant oligodendrogliomas.ETV/Pea3家族转录因子编码基因在CIC突变型少突胶质细胞瘤中过表达。
Genes Chromosomes Cancer. 2015 Dec;54(12):725-33. doi: 10.1002/gcc.22283. Epub 2015 Sep 10.
9
Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.靶向二代测序检测法在福尔马林固定石蜡包埋脑胶质瘤标本中检测 1p/19q 共缺失的效用。
Hum Pathol. 2022 Aug;126:63-76. doi: 10.1016/j.humpath.2022.05.001. Epub 2022 May 10.
10
Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.世界卫生组织(WHO)II级和III级弥漫性胶质瘤中1号染色体短臂(1p)和19号染色体长臂(19q)状态与O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)、p53和Ki-67表达的相关性:一项临床病理研究
Neuropathol Appl Neurobiol. 2009 Aug;35(4):367-379. doi: 10.1111/j.1365-2990.2008.01002.x. Epub 2008 Nov 18.

引用本文的文献

1
Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma.伏立西尼在非强化复发性中枢神经系统WHO 3级少突胶质细胞瘤中的扩大应用
Biomedicines. 2025 Jan 15;13(1):201. doi: 10.3390/biomedicines13010201.
2
FUBP1 in human cancer: Characteristics, functions, and potential applications.人类癌症中的FUBP1:特征、功能及潜在应用
Transl Oncol. 2024 Oct;48:102066. doi: 10.1016/j.tranon.2024.102066. Epub 2024 Jul 26.
3
IDH inhibition in gliomas: from preclinical models to clinical trials.IDH 抑制剂在脑胶质瘤中的应用:从临床前模型到临床试验。
Nat Rev Neurol. 2024 Jul;20(7):395-407. doi: 10.1038/s41582-024-00967-7. Epub 2024 May 17.
4
Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis.IDH 突变型胶质瘤的基因组特征:MYCN 扩增型 IDH 突变型星形细胞瘤预后最差。
Sci Rep. 2023 Apr 25;13(1):6761. doi: 10.1038/s41598-023-32153-y.
5
Signaling pathways in brain tumors and therapeutic interventions.脑肿瘤中的信号通路与治疗干预。
Signal Transduct Target Ther. 2023 Jan 4;8(1):8. doi: 10.1038/s41392-022-01260-z.
6
Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.通过研究神经发生和相关神经源性基因/信号通路在 GBM 发展中的作用来追溯胶质母细胞瘤的起源:系统评价。
World J Surg Oncol. 2022 May 10;20(1):146. doi: 10.1186/s12957-022-02602-5.
7
Oligodendroglioma: A Review of Management and Pathways.少突胶质细胞瘤:治疗与途径综述
Front Mol Neurosci. 2021 Oct 5;14:722396. doi: 10.3389/fnmol.2021.722396. eCollection 2021.
8
Computational analysis of sense-antisense chimeric transcripts reveals their potential regulatory features and the landscape of expression in human cells.正义-反义嵌合转录本的计算分析揭示了它们潜在的调控特征以及在人类细胞中的表达情况。
NAR Genom Bioinform. 2021 Aug 25;3(3):lqab074. doi: 10.1093/nargab/lqab074. eCollection 2021 Sep.
9
FUBP1 mediates the growth and metastasis through TGFβ/Smad signaling in pancreatic adenocarcinoma.FUBP1 通过 TGFβ/Smad 信号通路在胰腺腺癌中介导生长和转移。
Int J Mol Med. 2021 May;47(5). doi: 10.3892/ijmm.2021.4899. Epub 2021 Mar 2.
10
Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients.血管内皮生长因子 A、血管内皮生长因子受体 1-3 和神经纤毛蛋白 1-2 对 WHO 分级 II 级和 III 级脑膜瘤患者无进展生存期和总生存期的影响。
J Mol Histol. 2021 Apr;52(2):233-243. doi: 10.1007/s10735-020-09940-2. Epub 2021 Feb 2.